Renal cell carcinoma

  title={Renal cell carcinoma},
  author={Brian I. Rini and Steven C. Campbell and Bernard J. Escudier},
  journal={The Lancet},

Figures and Tables from this paper

Adjuvant Therapy for Renal Cell Carcinoma
The development of adjuvant therapy requires the proper identification of patients at highest risk of relapse; the ability to predict the recurrence has much room for improvement.
Adjuvant Therapy for High-Risk Renal Cell Carcinoma
A number of trials evaluating other adjuvant treatments for high-risk RCC are currently underway including studies evaluating immune checkpoint inhibitors and cytokine immunotherapy, cancer vaccines, hormonal therapy, and radiation.
Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
The armamentarium for the systemic therapy of advanced renal cell carcinoma (RCC) has undergone dramatic changes over the past 6 years, and one noteworthy new class of agents that has yielded durable responses is programmed death (PD)-1 inhibitors, which target a T-lymphocyte checkpoint and are heralding a resurgence of immunotherapy.
New perspectives in the treatment of metastatic renal cell carcinoma.
Multi-modal treatment for metastatic renal cancer: the role of surgery
  • P. Russo
  • Medicine
    World Journal of Urology
  • 2010
Carefully selected patients with good performance status undergoing nephrectomy and subsequent metastasectomy may experience prolonged survival in the range of 30 months, which could be attributed to a combination of patient selection factors and the surgical resections.
Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
The immune response obtained with DC vaccine combined with the antiangiogenic effect of sunitinib and the potential benefits of cytoreductive nephrectomy in advanced disease could represent a new option in the treatment of metastatic RCC.
Targeted therapies for non-clear renal cell carcinoma
This review will focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma: papillary I and II, chromophobe, and collecting duct.
Renal cell cancer: overview of the current therapeutic landscape
A comprehensive in-depth review of RCC is presented in an attempt to provide evidence-based recommendations and future perspectives for practicing oncologists.
Therapeutic challenges in renal cell carcinoma.
The current understanding of diagnostic challenges and the mechanism-based clinical evidence on therapeutic management of advanced RCC are discussed.


Immunotherapy for advanced renal cell cancer.
It has been established that reduced doseinterleukin-2 given by intravenous bolus or by subcutaneous injection provides equivalent survival to high dose interleuk in-2 with less toxicity, and results indicate that interferon-alfa is superior to controls.
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.
Cytoreductive nephrectomy appears to improve significantly overall survival in patients with metastatic renal cancer treated with interferon immunotherapy independent of patient performance status, the site of metastases and the presence of measurable disease.
Renal cell carcinoma: analysis of 31 cases with assessment of endocrine therapy
Factors influencing survival include the duration of the interval between diagnosis of the primary tumor and appearance of metastases and the association of certain paraneoplastic syndromes.
Postoperative Irradiation in Localized Renal Cell Carcinoma: The Rambam Medical Center Experience
Tumor invasion of the renal vessels and stage of disease were correlated with survival, and postoperative irradiation did not improve the survival of patients with RCC and showed toxicity, it is not recommended.
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferons therapy alone.
The value of postoperative radiotherapy in advanced renal cell cancer.
In the authors' opinion postoperative radiotherapy reduces the probability of local recurrences in selected patients, mainly with pathologic stage T3N0, but its impact on survival is minimal.